Document is current

Article History

Received: 11 October 2024

Accepted: 24 May 2025

First Online: 6 August 2025

Declarations

:

: This study was sponsored by Seagen Inc (which was acquired by Pfizer in December 2023) in collaboration with Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA. CA reports financial relationships with AstraZeneca, Athenex, Eisai, Elucida, G1 Therapeutics, Genentech, Immunomedics, IPSEN, Jones & Bartlett, Lilly, Merck, Nektar, Novartis, Pfizer, Puma Biotechnology, Seagen Inc, Tesaro, UpToDate, and Zion Pharma. EN, KB, BTP, and NRMS were, at the time of this study, employees of and held stock and/or stock options in Seagen Inc. SW and YL are employees of Genesis Research, which was a paid consultant to Seagen (acquired by Pfizer in December 2023) in connection with the development of this manuscript. PAK reports financial relationships with Amgen, AstraZeneca, Eisai, H3 BioMedicine, Lilly, Macrogenics, Pfizer, Polyphor, Roche/Genentech, and Sanofi. JM reports a consulting/advisory board role for AstraZeneca, Clovis, Genentech, Glaxo SmithKline, Novartis, Pfizer, Puma, Sanofi Genzyme, and Seagen Inc and a research (institutional) advisory role for Seagen Inc, Pfizer, AstraZeneca, and Olema.

: This study was performed in accordance with relevant guidelines and regulations. Since this study did not involve the collection, use, or transmittal of individually identifiable data, institutional review board approval was not required.

: As this study did not enroll patients and the data sets used are devoid of patient identifiable information, informed consent was not required.

: Not applicable.